A

AbbVie

Global biopharmaceutical company developing medicines

Principal AI Engineer 2

Full-TimeUpdated on 10/23/2026
$141.5k - $268.5k/yr+ Long-term incentive program
Expert
Bachelor's, Master's, PhD
North Chicago, IL, USA
Hybrid
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • A Bachelor's degree with 9 years of experience, a Master's degree with 8 years of experience, or a PhD with 4 years of experience in Computer Science, Artificial Intelligence, Machine Learning, Data Science, Engineering, or a related technical discipline is required.
  • Demonstrated experience designing, deploying, and operating production-scale artificial intelligence and machine learning systems is required.
  • Strong experience in artificial intelligence/platform engineering, including scalable platforms, reusable components, and production-grade artificial intelligence solutions, is required.
  • Demonstrated experience designing, building, deploying, and supporting solutions using Amazon Web Services systems and services is required.
  • Strong software and cloud engineering practices, including secure design, automated testing, continuous integration and continuous delivery, containerization, monitoring, and operational support, are required.
  • Experience working in a regulated environment is required; pharmaceutical, biotechnology, healthcare, medical device, or life sciences experience is preferred.
  • Experience supporting the full solution lifecycle, including feasibility, design, development, testing, validation, deployment, and ongoing operations, is required.
  • A strong understanding of risk management, validation, change control, data integrity, cybersecurity, privacy, documentation, and quality requirements is required.
  • Demonstrated ability to manage complex stakeholders, influence technical and business decisions, and collaborate across organizational boundaries is required.
  • Excellent communication with senior leaders, technical teams, scientific experts, business partners, and external collaborators is required.
  • Demonstrated innovation and mentoring experience, including advancing engineering practices and delivering measurable impact, is required.
Responsibilities
  • Define and advance artificial intelligence engineering strategy, architecture, standards, and roadmaps aligned with business and technology objectives.
  • Architect and build secure, scalable, reusable artificial intelligence platforms, services, developer tools, and components that support enterprise adoption.
  • Lead production-grade artificial intelligence solutions from ideation and prototyping through development, testing, validation, deployment, monitoring, continuous improvement, and retirement.
  • Integrate artificial intelligence platforms with Amazon Web Services and enterprise data, software, security, identity, and infrastructure environments.
  • Establish practices for evaluation, testing, versioning, release management, observability, performance monitoring, incident response, and operational support.
  • Apply risk-based approaches to compliance, GxP, data integrity, privacy, cybersecurity, documentation, traceability, human oversight, and responsible artificial intelligence.
  • Partner with Quality, Regulatory, Legal, Privacy, Information Security, scientific, technical, and business stakeholders to deliver fit-for-purpose solutions.
  • Serve as a trusted technical advisor, facilitate alignment, influence decisions without direct authority, and communicate complex tradeoffs and recommendations to technical and non-technical audiences.
  • Evaluate emerging technologies, lead innovation and proof-of-concept efforts, and guide promising solutions into sustainable production capabilities.
  • Mentor engineers, advance engineering maturity, promote knowledge sharing, and represent the company in relevant technical communities and partner engagements.
Desired Qualifications
  • Experience with enterprise artificial intelligence governance, responsible artificial intelligence, model validation, human oversight, and artificial intelligence lifecycle management.
  • Experience with MLOps and production engineering, including model evaluation, application programming interfaces, microservices, continuous integration and continuous delivery, observability, and infrastructure as code.
  • Open-source contributions or technical thought leadership through publications, patents, or industry working groups.
  • Experience leading cross-functional product development from feasibility through validation and production implementation.
  • Enterprise artificial intelligence or platform experience, including Amazon Web Services architecture, governance, security, and integration with enterprise environments.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.